Original Article

Osteoporosis International

, Volume 16, Issue 12, pp 1545-1557

First online:

Fracture Reduction Affects Medicare Economics (FRAME): Impact of increased osteoporosis diagnosis and treatment

  • Alison B. KingAffiliated withPublic Policy, Procter & Gamble Pharmaceuticals Email author 
  • , K. G. SaagAffiliated withDepartment of Medicine, University of Alabama at Birmingham
  • , R. T. BurgeAffiliated withProcter & Gamble Pharmaceuticals, 8700 Mason-Montgomery RdOhio State University
  • , M. PisuAffiliated withCenter for Outcomes and Effectiveness Research and Education (COERE), University of Alabama at Birmingham
  • , N. GoelAffiliated withProcter & Gamble Pharmaceuticals, 8700 Mason-Montgomery RdUniversity of Texas Medical Branch

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


Osteoporosis is a common, debilitating disease affecting US Medicare beneficiaries, yet diagnosis and treatment lag behind medical advances. We estimated the cost of fractures to the Medicare program and the impact of increasing osteoporosis diagnosis and treatment. A Markov model was used to predict fracture incidence and costs in postmenopausal women aged 65 years and older, over 3 years (2001–2003). Only 1.80 million women were estimated to receive a Medicare-reimbursed bone mineral density (BMD) test in 2001. We evaluated the budget impact of testing an additional 1 million women from Medicare and patient perspectives. These women were stratified into high-risk (osteoporotic with prevalent vertebral fracture) and moderate-risk (without prevalent vertebral fracture) groups. During 2001–2003, an estimated 2.39 million fractures occurred among the 5.11 million women aged 65+ with osteoporosis, at a cost to Medicare of $12.96 billion. We projected that BMD testing of an additional 1 million women in 2001 would result in treatment of 440,000 new patients with a bone-specific medication, preventing over 35,000 fractures over the 3 years. The decrease in fractures would produce a net discounted savings to the Medicare budget of $77.86 million. Medicare’s hospital inpatient cost would decrease by $115.41 million and long-term care cost by $43.51 million, more than offsetting incremental outpatient cost of $81.07 million. Patients would benefit from fracture avoidance, but their out-of-pocket medical costs would increase by $63.49 million during 2001–2003, or $1,771 per fracture avoided. Sensitivity analyses showed that savings to the Medicare program varied in proportion to the unit cost of fractures, fracture risk of the populations tested, treatment rate, and adherence to therapy. Increased osteoporosis diagnosis may produce savings for the Medicare program if interventions are targeted to women at elevated risk for fracture and may be budget neutral if all older women are screened.


Bone densitometry Economics Fractures Medicare Osteoporosis Treatment